EndoPredict lacks clinical evidence showing that patients with EPclin* high-risk results may benefit from chemotherapy
EndoPredict may lead to unnecessary chemotherapy treatment based on its risk classification result
EndoPredict has not been validated to show prediction of chemotherapy benefit
Only the Oncotype DX Breast Recurrence Score test result has been proven to predict chemotherapy benefit in both node-negative and node-positive patients.2,4
*EPclin algorithm: nodal status + tumor size + EP (molecular score).
HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; NSABP B-20 = National Surgical Adjuvant Breast and Bowel Project; TAILORx = Trial Assigning Individualized Options for Treatment.